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The drug-loaded composite electrospun nanofiber has attracted more attention in biomedical field, especially in
cancer therapy. In this study, a composite nanofiber was fabricated by electrospinning for cancer treatment. Firstly,
the carbon nanotubes (CNTs) were selected as carriers to load the anticancer drug—doxorubicin (DOX) hydrochloride.
Secondly, the DOX-loaded CNTs (DOX@CNTs) were incorporated into the poly(lactic-co-glycolic acid) (PLGA) nanofibers
via electrospinning. Finally, a new drug-loaded nanofibrous scaffold (PLGA/DOX@CNTs) was formed. The properties of
the prepared composite nanofibrous mats were characterized by various techniques. The release profiles of the
different DOX-loaded nanofibers were measured, and the in vitro antitumor efficacy against HeLa cells was also
evaluated. The results showed that DOX-loaded CNTs can be readily incorporated into the nanofibers with relatively
uniform distribution within the nanofibers. More importantly, the drug from the composite nanofibers can be released
in a sustained and prolonged manner, and thereby, a significant antitumor efficacy in vitro is obtained. Thus, the
prepared composite nanofibrous mats are a promising alternative for cancer treatment.
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Up to date, cancer is still one of the deadliest killers to
human lives, because both the incidence and mortality
rates of cancers (including lung, stomach, liver, prostate,
colorectum, breast cancers, and so on) are continuously
rising [1, 2]. Unfortunately, it can be said that, as of yet,
despite tremendous efforts have been made in the cancer
therapy, there is still no efficient methods for prevention
of cancer relapse, as well as the prevention of their
spread and metastasis [3]. A wholesale and thorough
cure for cancers remains elusive for a number of reasons.
Some of these reasons including late stage diagnosis, inad-
equate resection during surgery, and cancer cell migration
often lead to cancer recurrence [4, 5]. Local cancer recur-
rence after “curative” treatment remains a major clinical* Correspondence: ypbinzhou@163.com
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provide a link to the Creative Commons liceproblem for most cancers. As we all know, current thera-
peutic approaches for malignant tumors include surgery,
radiotherapy, chemotherapy, hyperthermia, immunother-
apy, hormone therapy, stem cell therapy, and combina-
tions of these modalities [6]. Chemotherapy, as a general
therapeutic approach, has been widely investigated to treat
a variety of malignant cancer cells [7, 8]. Doxorubicin
(DOX), a class I anthracycline antibiotic, is an excellent
broad-spectrum anticancer drug for treating many types
of cancers [9]. It can effectively kill cancerous cells by
damaging DNA and its replication via the mechanisms of
intercalation between nucleotides, inhibition of topoisom-
erase II, and generating oxygen free radicals [10]. How-
ever, the clinical application of free DOX is known to have
short life and low therapeutic index, and a large dosage of
administration dosages are required to achieve the desir-
able therapeutic effect, which also causes severe toxicity
to normal tissues, for example, cardiotoxicity and mye-
losuppression [10, 11]. Therefore, the development of aticle is distributed under the terms of the Creative Commons Attribution
mons.org/licenses/by/4.0/), which permits unrestricted use, distribution,
you give appropriate credit to the original author(s) and the source,
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is necessary.
Nanotechnology as an emerging technology may be a
reasonable choice and an effective strategy for solving the
above problem. According to the report from the National
Cancer Institute (NCI) in USA, nanotechnology seeks
to exploit distinct technological advances towards cancer
prevention and treatment [12]. Electrospinning is a versatile
technique to fabricate two-dimensional nanofibers. Electro-
spun nanofibers have recently received significant atten-
tions in biomedical applications because they possess large
surface area-to-volume ratio, high interfiber porosity with
tunable pore size, low hindrance for mass transfer, flexible
handling, adjustable morphology, and well mechanical
strength, which would make nanofibers use as therapeutic
patch for drug delivery [13, 14]. The controlled drug release
from drug-loaded nanofibrous mat at a rate according to
the need could be realized by properly designed architec-
ture, porosity, fiber diameter, drug incorporation manner,
and composition of nanofibers [15]. In addition, the medi-
cated nanofibrous products can be easily set to the targeted
site by adjusting their morphology [15]. Thus, the drug-
loaded nanofibers can be targeted delivery to the desired
target tissues with controlled release where drug is released
in a certain way for preventing local tumor recurrence
after surgery. Aliphatic biodegradable polyester, such as
poly(lactic acid-co-glycolic acid) (PLGA), is widely used
to form electrospun nanofibers in various clinic and
xsimplebiomedical research applications because it has
excellent biocompatibility and biodegradability [10, 16].
However, the simple introduction of drug into polymer
matrix always leads to inevitable burst drug release,
since the drug molecules might migrate on or near the
fiber surfaces because of the high ionic strength in drug/
polymer solution and the rapid evaporation of the solvent
during electrospinning. To address this limitation, it is
highly desirable to develop efficient nanocarrier-mediated
nanofibrous delivery systems which may serve as barrier
for improving the safety of anticancer drugs and avoid
drug premature burst release under physiological con-
ditions [7, 17–21]. In fact, several nanoscale carriers
such as mesoporous silica nanoparticles [22], hydroxyapa-
tite [10], and liposome [23] have recently been incorpo-
rated into electrospun nanofibers for potential anticancer
therapy, from which the prolonged drug release with tun-
able drug release kinetics could be achieved. Carbon
nanotubes (CNTs), which are rolled-up seamless cylinder
of graphene sheets, have gained extensive attention in the
past decade [24]. CNTs are classified as single-walled car-
bon nanotubes (SWNTs) or multi-walled carbon nanotubes
(MWNTs), which depend on the number of graphene layer
which a single nanotubes is composed [24]. In recent years,
efforts have also been devoted to explore the potential
biomedical application of CNTs. Benefitting from theirsuperior heir distinct properties, especially, the bio-
compatibility in the physiological condition, CNTs have
been one of the most promising inorganic nano-sized
vectors for anticancer drugs, proteins, genetic therapeu-
tics, and biological imaging agent delivery [8, 24, 25]. Up
to now, the development of CNTs-doped PLGA nanofi-
bers for cancer therapy has not been reported to the best
of our knowledge. The objective of this work, therefore,
was to examine the hypothesis of preparing a sustained
anticancer drug release system by doping drug-loaded
CNTs into PLGA nanofibers.
In this present work, we have successfully fabricated
DOX-loaded PLGA/CNTs composite nanofibrous mats
by using electrospinning technique and then have assessed
its antitumor efficacy against HeLa cells. The morphology
and structure of electrospun nanofibers were characterized.
After the evaluation of the drug loading capacity and effi-
ciency, the in vitro release characteristics of DOX from the
composite nanofibers were also measured. And further
cytotoxicity experiments demonstrate that the drug-loaded
nanofibers exhibit obviously therapeutic effect for cancer
cell, implying that it may become a novel therapy strategy




PLGA with lactic acid/glycolic acid ratio of 75:25 (Mw =
110 kDa) was purchased from Daigang Biomaterials Inc.
(Jinan, China). Carbon nanotube (CNTs) was purchased
from Chengdu Organic Chemicals Co., Ltd. Doxorubicin
(DOX) hydrochloride was purchased from Beijing Huafeng
United Technology Co., Ltd. HeLa cells were supplied by
Institute of Biochemistry and Cell Biology (the Chinese
Academy of Sciences, Shanghai, China). Dulbecco’s Modi-
fied Eagle’s Medium (DMEM), fetal bovine serum (FBS),
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide
(MTT), trypsin, penicillin (100 U/mL), and streptomycin
(100 mg/mL) were all purchased from Shanghai Yuanxiang
Medical Equipment Co., Ltd. All other chemicals were
obtained from Sino-pharm Chemical Reagents Co., Ltd.
(Shanghai, China).
Fabrication of DOX-loaded CNTs
The DOX-loaded CNTs (DOX@CNTs) were fabricated
by the previously described method with some modifica-
tions [10]. Briefly, DOX aqueous solution (1 mg/mL)
was prepared, and 20 mg CNTs was dispersed into DOX
solution. The mixture was stirred under dark conditions
for 12 h and vacuumed slowly at room temperature for
3 h. The DOX@CNTs were collected by centrifugation
(10,000 rpm, 10 min) and washed with phosphate-buffered
saline (PBS) (pH = 7.4) solution to remove the dissociative
DOX. The obtained DOX@CNTs was vacuum-dried at
Fig. 1 Schematic illustration for the process of fabrication of
PLGA/DOX@CNTs electrospun composite nanofibers
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evaluate the loading efficiency of DOX, the supernatant
was collected, and the DOX concentration in the super-
natant was analyzed by using UV-vis spectrophotometer at
488 nm. The loading percentage of DOX in CNTs was
calculated as follows:
Loading percentage (%) = (initial weight of DOX−re-
sidual weight of DOX)/weight of DOX-loaded CNTs ×
100 %.
Preparation of PLGA/DOX@CNTs Nanofibers
The PLGA/DOX@CNTs composite nanofibers were
fabricated by using a blend electrospinning. Firstly, the
prepared DOX@CNTs was completely dispersed in
hexauoroisopropanol (HFIP) and the PLGA was added
into the above solution at 20 w/v %, and then stirred
thoroughly to form a homogenous spinning solution.
The solution was placed into a 5-mL plastic syringe
with an 18-gauge blunt-ended needle. The electrospin-
ning parameters were set as follows: the applied volt-
age of 20 kV, the collection distance of 15 cm, and the
solution flow rate of 1.0 mL/h controlled by a syringe
pump (789100C, Cole-Parmer Instruments, USA). The
collected nanofibers were vacuum-dried at least 72 h
to remove the residual solvent before further use.
The CNTs content in the nanofibers were 0.5, 1, and
2 wt. % (CNTs relative to PLGA), and the corresponding
DOX contents in nanofibers can be calculated from the
loading efficiency of CNTs. For comparison, the PLGA/
DOX composite nanofibers were also prepared by elec-
trospinning with the same DOX contents.
Characterization
The morphology of the composite nanofibers was ob-
served by a scanning electron microscope (SEM, Hitachi
TM-1000, Japan), and the distribution of DOX@CNTs
in the nanofibers was characterized by a transmission
electron microscope (TEM, JEM-2100, Japan) at an op-
erating voltage of 200 kV. At least 40 nanofibers were
selected from different SEM image, and the nanofiber
diameter was measured using Image J 1.40 G software
(NIH, USA). The fluorescent images of the different com-
posite nanofibers were observed by a fluorescence micro-
scope (Nikon TS100, Japan). The thermogravimetric
analysis (TGA) was conducted on a thermal analyzer (TG
209 F1, Germany) from the room temperature to 600 °C
at a heating rate of 10 °C/min. The tensile testing of the
composite nanofibers with a planar area of 50 × 10 mm
was measured using a universal material tester (H5K-S,
Hounsfield, UK) with a cross-head speed of 10 mm/min.
In Vitro Drug Release
The DOX release behaviors from the DOX-loaded
samples including PLGA/1.5 % DOX and PLGA/1.5 %DOX@2 % CNTs electrospun nanofibers were carried
out in PBS at pH 7.4. Briefly, a certain amount of the
different DOX-loaded samples with the same content
of DOX were put in a dialysis bag (cutoff molecular
weight 7000 Da), and the bag was immersed in 15 mL
of PBS (pH 7.4) at 37 °C in a thermostatted shaker
with shaking at a rate of 100 rpm. At selected time in-
tervals, the release medium (5 mL) was taken out and
supplied with the same volume of fresh PBS. The concen-
tration of DOX in the release media was determined by
recording the absorbance of DOX at 480 nm using UV-vis
spectrophotometer.Cytotoxicity Evaluation of Different DOX-Loaded Samples
HeLa cells were cultured in the DMEM medium sup-
plemented with 10 % FBS 100 U/mL penicillin and
100 μg/mL streptomycin. The cells were cultured at
37 °C in a humidified incubator containing 5 % CO2.
MTT assay was employed to evaluate the viability of
the HeLa cells cultured with different samples. For all
experiments, cells were harvested by using trypsin so-
lution and resuspended in the fresh DMEM medium.
Before cell seeding, the samples were sterilized under
UV light for 3 h and washed with PBS for three times.
For MTT assay, HeLa cells at a density of 1 × 104 cells/
well were seeded in 24-well plates and cultured for 12 h
to allow cells to attach. Then, the medium was replaced
with a fresh medium (negative control) and the medium
containing the PLGA/2 % CNTs, free DOX (positive
control), PLGA/1.5 % DOX, and PLGA/1.5 % DOX@2 %
CNTs composite nanofibers, and the total DOX
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50 mg/mL. After the cells were cultured for 24 h, the cells
were washed twice with PBS and the 360-μL fresh culture
medium and 40-μL MTT solution (5 mg/mL in PBS) were
then added to each well. The cells were incubated for an-
other 4 h. Thereafter, the 400 μL suspension was discarded,
and 400 μL of DMSO was added to each well to completely
dissolve the precipitate by stirring for 15 min. Then, 100 μL
of the supernatant was transferred to 96-well microplates,
and the OD value was measured with a microplate reader
(MK3, Thermo, USA) at 492 nm. The relative cell via-
bility was calculated by dividing the mean OD value of the
control group, and the average value was obtained from five
parallel samples.
For confocal microscopy observation, HeLa cells were
seeded into 24-well plates at a density of 1 × 104 cells/well
and incubated for 24 h. Then, the culture medium wasFig. 2 The morphology and diameter distributions of PLGA and PLGA/DOX@
CNTs, b PLGA/1.5 % DOX@1 % CNTs, and c PLGA/1.5 % DOX@2 % CNTs
corresponding diameter distributions of a–cremoved, and the cells were incubated with PLGA/2 %
CNTs, free DOX, PLGA/1.5 % DOX, and PLGA/1.5 %
DOX@2 % CNT composite nanofibers (DOX concentra-
tions at 25 μg/mL) for another 24 h. After washing with
PBS twice, the cells were fixed with 4 % paraformaldehyde
for 10 min. The cells were then permeabilized in 0.1 %
Triton X-100 in PBS for 5 min, followed by blocking with
1 % BSA for 20 min. The F-actin of cells was stained by
using Alexa Fluor 488® phalloidin solution for 10 min. Fi-
nally, all samples were washed several times with PBS
and observed by confocal laser scanning microscope
(CLSM).
Results and Discussion
Characterization of Composite Nanofibers
Figure 1 shows the brief fabrication process of PLGA/
DOX@CNTs composite nanofibers. DOX was firstly loadedCNTs composite nanofibers. SEM images of a PLLA/1.5 % DOX@0.5 %
nanofibers. d–f The corresponding TEM images of a–c. g–i The
Fig. 3 Typical tensile stress-strain curves of electrospun PLGA
nanofibers, PLGA/0.5 % CNTs, PLGA/1 % CNTs, and PLGA/2 %
CNTs composite nanofibers
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obtained DOX@CNTs was mixed with the PLGA solution
to fabricate PLGA/DOX@CNTs composite nanofibers by
electrospinning.
It is known that the morphology of electrospun nano-
fibers is influenced by various parameters, such as the
concentration of polymers, applied voltage, and flow
rate of solution. For the organic/inorganic composite
nanofibers, the morphology and the diameter can be
dramatically affected by the content of inorganic com-
ponent in polymers [20, 26]. Therefore, it is encouraged
to investigate the effects of the content of CNTs on the
nanofibrous morphology and diameter. Figure 2 shows
the morphology and diameter distribution of the electro-
spun nanofibers. As shown in Fig. 2a, it can be clearly seen
that a smooth surface morphology and relatively uniform
fibrous diameter were observed in PLGA/0.5 % CNTs, with
the average diameter of 528.5 nm (Fig. 2g). When the con-
tent of CNTs was 1 % (Fig. 2b), a similar fiber morphology
was seen. While the fiber diameter slightly increased,
the average diameter of PLGA/1 % CNTs was 814.1 nm
(Fig. 2h). When the content of CNTs was up to 2 %,
the fibers of PLGA/2 % CNTs were changed to be swollen
to a certain extent (Fig. 2c), but the fiber morphology still










0 6.78 ± 1.00 177.38 ± 24.82 170.71 ± 46.22
0.5 2.87 ± 0.30 65.43 ± 18.32 76.50 ± 2.30
1 4.08 ± 0.11 78.13 ± 12.94 145.53 ± 8.67
2 4.45 ± 0.40 97.33 ± 2.10 142.25 ± 3.302 % CNTs was increased to 1058.8 nm (Fig. 2i). As a re-
sult, the average diameter of the fibers gradually increased
with increasing content of CNTs, which can be attributed
to the increase in viscosity of the solution after the
addition of a large amount of CNTs [26, 27]. Additionally,
the TEM images of Fig. 2d–f clearly shows that CNTs can
be homogenously distributed within the nanofibers, and
more CNTs appeared with the increase of the CNTs
content. Hence, 2 % of CNTs was an alternative in the
following experiments.
Figure 3 shows the typical tensile strain-stress curves
of neat PLGA and the PLGA/CNTs composite nanofibers
with different CNTs contents. The mechanical properties
of these nanofibers are summarized in Table 1. It can be
found that the addition of CNTs affected the mechanical
properties of the composite nanofibers, whose tensile
strength, elongation at break, and Young’s modulus
were smaller than that of the neat PLGA nanofibers.
This tendency was similar with the mesoporous silica
nanoparticles-embedded nanofibers, which may result
from the aggregation of CNTs in hybrid nanofibers and
poor interfacial adhesion between the CNTs and the
PLGA matrix [22]. Furthermore, among the composite
nanofibers, the tensile strength increased with the in-
creasing of CNTs contents, which was basically in
agreement with the data of the elongation at break.
However, the Young’s modulus of PLGA/1 % CNTs was
greater than that of the other composite nanofibers. For
example, the Young’s modulus for composite nanofibers
with 1 % of CNTs content was 145.53 MPa as compared
to 76.50 MPa for PLGA/1 % CNTs and 142.25 MPa for
PLGA/2 % CNTs nanofibers.
TGA was used to examine the thermal properties of
obtained electrospun nanofibers and confirm the suc-
cessful incorporation of drug-loaded CNTs within the
composite nanofibers. As seen from Fig. 4, a moderateFig. 4 TGA thermograms of neat PLGA and PLGA/1.5 % DOX@2 %
CNTs composite nanofibers
Fig. 5 Fluorescent images of PLGA/DOX and PLGA/DOX@CNTs composite nanofibers. a PLGA/0.5 % DOX, b PLGA/1.0 % DOX, c PLGA/1.5 % DOX,
d PLGA/1.5 % DOX@0.5 % CNTs, e PLGA/1.5 % DOX@1 % CNTs and f PLGA/1.5 % DOX@2 % CNTs composite fibers
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to the vaporization of residual water in nanofibers. Then,
a sharp weight loss between 250 and 400 °C can be clearly
observed. The weight loss percentages of PLGA and
PLGA/1.5 % DOX@2 % CNTs were calculated to be 2.5
and 4.1 %, respectively, suggesting that about 2 % of
CNTs had been successfully incorporated into the fi-
bers, which was almost equal to the initially added
weight of CNTs. Additionally, the TGA results also re-
vealed the effect of added CNTs on the thermal stability of
composite nanofibers. The onset degradation temperature
(Tonset) of the PLGA nanofibers was 247 °C, whereas the
Tonset value (270 °C) of PLGA/1.5 % DOX@2% CNTs
was prominently increased, indicating that the addition
of CNTs can improve the thermal stability of the com-
posites, which was similar to the results obtained by
Qiu et al. [22].Fig. 6 The cumulative DOX release profiles from PLGA/1.5 % DOX
and PLGA/1.5 % DOX@2 % CNTs nanofibrous matsDOX Loading and Release
To investigate the DOX loading and releasing behavior
of composite nanofibers, DOX-loaded CNTs were firstly
prepared. The high loading percentage (81.5 %) was at-
tributed to the special sp2-hybridized carbon surfaces
and a large surface area of CNTs [28]. Then, the DOX-
loaded CNTs were incorporated into PLGA nanofibers
via electrospinning. Fluorescence microscopy was used
to observe the DOX-loaded composite nanofibers via the
red fluorescence of DOX (Fig. 5). From Fig. 5a–c, we
can see that all the PLGA/DOX samples displayed a
uniform red fluorescence, indicating the homogeneous
dispersion of DOX in the nanofibers. Similarly, the red
fluorescence of DOX can be clearly observed in the
PLGA/DOX@CNTs nanofibers. Nevertheless, some localred spots appeared as compared to their PLGA/DOX
counterparts (Fig. 5d–f ), which may be caused by the
partial aggregation of CNTs in the nanofibers. This result
also revealed that the DOX@CNTs can be incorporated
into PLGA nanofibers with relatively uniform distribution
within the nanofibers.
The DOX release behavior was investigated under stim-
ulated physiological environment (pH = 7.4) at 37 °C. For
comparison, the release profiles of PLGA/1.5 % DOX and
PLGA/1.5 % DOX@2 % CNTs electrospun nanofibers
containing the equivalent DOX contents were studied. As
shown in Fig. 6, both electrospun mats exhibited relatively
rapid release rate at the beginning 12 h, which was re-
sulted from the fast diffusion of DOX molecules closed to
the nanofibers surface. Afterwards, the DOX was released
more slowly from CNTs-incorporated mats than that from
Fig. 7 Cell viability of HeLa cells treated with different samples with DOX concentrations ranging from 10 to 50 μg/mL
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fectively protect drug molecules from premature leakage,
which was beneficial to decrease side effect of anticancer
drugs. Moreover, the release behavior of PLGA/1.5 %
DOX@2 % CNTs sustained for 8 days with nearly 50 % of
total drug released. The steady and tardy DOX release
endows the hybrid mats with a desired therapeutic con-
centration of anticancer drug over an extended period of
time, which was efficient to kill cancer cells.Fig. 8 Confocal laser scanning microscopy images of HeLa cells treated wi
DOX@2 % CNTs. DOX concentration was 25 μg/mL. The red fluorescence in
Fluor 488® phalloidin-stained F-actin. Scale bars = 100 μmIn Vitro Antitumor Effect
In antitumor application of drug-containing materials,
a high antitumor effect was needed. Therefore, we next
investigated the antitumor activity of the DOX upon re-
lease from DOX-loaded composite nanofibers by MTT
assay. Figure 7 shows the cell viability of HeLa cells treated
with different samples with DOX concentrations ranging
from 10 to 50 μg/mL for 24-h incubation. As compared
with the control (medium only), it was obvious that theth PLLA/2 % CNTs, free DOX, PLLA/1.5 % DOX, and PLLA/1.5 %
dicates the released DOX. The green fluorescence represents Alexa
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to HeLa cells within the tested concentrations. But for
other groups (PLGA/1.5 % DOX, PLGA/1.5 % DOX@2 %
CNTs and free DOX), a dose-dependent cytotoxicity was
observed. For free DOX group, it showed a statistically sig-
nificant higher inhibition effect than other groups at all the
measured concentrations (P < 0.01). However, PLGA/1.5 %
DOX@2 % CNTs composite nanofibers showed a statisti-
cally significant lower inhibition effect than PLGA/1.5 %
DOX and free DOX when the DOX concentration was less
than 50 μg/mL (P < 0.01), which was due to the slow release
rate of DOX from the composite nanofibers. Additionally,
PLGA/1.5 % DOX and PLGA/1.5 % DOX@2 % CNTs
composite nanofibers started to have apparent cytotoxicity
only at DOX concentration of 25 μg/mL or above. It is
noted that the inhibition effect of PLGA/1.5 % DOX@2 %
CNTs composite nanofibers was equal to PLGA/1.5 %
DOX when the DOX concentration was 50 μg/mL but
lower than the free DOX. Although PLGA/1.5 % DOX@2 %
CNTs composite nanofibers have not shown the relatively
prominent anticancer efficacy compared with the PLGA/
1.5 % DOX and free DOX group from the MTT assay, but
we expected that a long-term growth inhibition in cancer
cells could be achieved with the sustained DOX release
from this matrix.
CLSM imaging technology was further employed to
gain more insights into the therapeutic effect caused by
PLGA/DOX@CNTs. The Alexa Fluor® 488 phalloidin
was used to label cytoskeleton and the red fluorescent
nature of DOX facilitated the in situ observation. As
shown in Fig. 8, it is worth noting that the free DOX,
PLGA/1.5 % DOX and PLGA/1.5 % DOX@2 % CNTs
could effectively inhibited the growth of HeLa cells,
because the drug treated cells displayed apparent morpho-
logical features of apoptosis after treatment for 24-h com-
pared with control. The cells incubated with PLGA/2 %
CNTs nanofibers showed no significant abnormality on
the morphology, indicating that the cytotoxicity was as-
sociated with the DOX molecule, not the nanocarrier.
Conclusions
In summary, we have reported a very effective and re-
producible route to prepare a drug delivery system based
on PLGA/CNTs composite nanofibers. The highly uni-
form and smooth nanofiber is successfully designed
and developed. By combining the CNTs, as a proof-of-
concept, we demonstrated that the PLGA/CNTs composite
nanofibers could be used for the sustained release of
the anticancer drug molecule DOX, which is important
for biomedical applications requiring the drug molecule to
maintain long-term anticancer efficacy. And the release
profiles clearly indicated that the DOX can be loaded
in the inner cavities or on the outside surface of the
CNTs weakening the initial burst release of DOX. Inaddition, our results indicated that the prepared PLGA/
DOX@CNTs nanofibers platform could effectively in-
hibit the cell viability of HeLa cells in vitro. Our results
shed light on a promising use of the PLGA/DOX@CNTs
composite nanofibers as a long-term drug release nano-
platform for chemotherapy in clinical cancer treatment.
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